Corporate Actions
Panacea Biotec rallies on bagging international vaccine supply contract

26-Dec-25   11:42 Hrs IST

Under the revision, the contract value for 2026 has been increased by $2.55 million (around Rs 23 crore) to $16.8 million, while the 2027 allocation rises by $2.70 million (around Rs 24 crore) to $15.18 million. Additionally, an extra award for 2027 worth $3.68 million (about Rs 33 crore) has been included, taking the total incremental value to $8.93 million (roughly Rs 80 crore) for the two years.

The international supply contract will be executed as per orders received from UNICEF during CY2026 and CY2027. UNICEF is expected to publish details of the award, including supplier name, vaccine, duration, total value, and awarded prices per product on its official website.

Panacea Biotec said the award does not involve any promoter or promoter group interest.

Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture, and marketing of vaccines in India and international markets.

The company reported a consolidated net loss of Rs 13.92 crore in Q2 FY26 as against a net profit of Rs 4.80 crore in Q2 FY25. Revenue from operations declined 4.2% year on year to Rs 141.13 crore in Q2 FY25.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.